Answers are grounded in this paper and cite their sources.
L-Type amino acid transporter 1 (LAT1) is highly expressed in various cancer cells, including lung cancer. However, its inhibition remains unclear. We used tissue microarrays (TMAs) from surgically resected lung cancer and autopsy specimens to assess LAT1 expression frequency and inter-tumor heterogeneity using immunohistochemistry. Additionally, we assessed the combined effects of targeted drugs and LAT1 inhibition in vitro and in vivo using human lung cancer cell lines. Among 127 lung cancer cases (96 TMAs and 31 autopsy specimens), LAT1 expression was observed in 36% (20/55) of small cell carcinomas, 90% (27/30) of squamous cell carcinomas, and 31% (13/42) of adenocarcinomas, including 33% (6/18) of driver mutation-positive adenocarcinomas. LAT1-positive cases had significantly shorter postoperative disease-free survival (DFS) (p = 0.005; hazard ratio [HR] = 3.703). LAT1 expression in autopsy specimens exhibited minimal intertumor heterogeneity in small cell and squamous cell carcinomas, with higher variability in adenocarcinomas. In human KRASG12C mutant lung cancer cell lines, the LAT1 inhibitor (JPH203) was ineffective as a single agent but synergistically increased the sensitivity of H23 and H2030 cell lines to the KRASG12C inhibitor (sotorasib) in vitro. In the H2030 xenograft model, JPH203 combined with sotorasib delayed tumor regrowth than that with sotorasib alone. These results indicate that LAT1 may be a therapeutic target in certain lung cancers, such as those with KRASG12C mutations.
No takes yet. Share an insight, caveat, or question.
Koba et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: